Table 2.

Data collection

	Day 0	Week 4	Week 24	Week 48
Informed consent	x
Randomisation	x
Demographics*	x
Framingham Risk Score	x		x	x
SF-12†	x		x	x
Body weight	x		x	x
Vital signs	x		x	x
Blood tests‡	x		x	x
HIV safety blood tests§	x	x	x	x
Transient elastography/Controlled Attenuated Parameter	x		x	x
CT¶	(x)		(x)	(x)
DEXA**	x		x	x
cIMT††	x		x	x
MRI substudy
Cardiac MRI‡‡	x			x
24 hours ECG Holter monitoring	x			x

*Age, gender, tobacco use, alcohol consumption, medication, medical history, nursing home residency and activities of daily living.

†12-Item Short-Form Health Survey (SF-12).

‡HIV safety blood tests: Plasma HIV-RNA and CD4 count.

§Blood tests: leucocytes, platelets, haemoglobin, creatinine, urea, sodium, potassium, bilirubin, alanine aminotransferase, lactate dehydrogenase, erythrocyte fraction. Metabolism: Fasting p-glucose, insulin, glycated haemoglobin, total cholesterol, high-density lipoprotein, low-density lipoprotein, very low-density lipoprotein, triglyceride. Inflammation: High-sensitive C reactive protein, interleukin 1 and 6. Coagulation: D-dimer, factor 2, 7 and 10, fibrinogen. Platelet function: soluble P-selectin, soluble glycoprotein VI. Endothelial function: Vascular cell adhesion molecule 1, intercellular adhesion molecule 1, cardiac: N-terminal pro-B-type natriuretic peptide, troponin T.

¶Low dose CT of thorax and abdomen to determine coronary artery calcium score, visceral adipose tissue, subcutaneous adipose tissue and liver steatosis.

**Dual energy X-ray absorptiometry (DEXA), optional.

††Carotid intima-media thickness (cIMT) determined by ultrasound.

‡‡Cardiac MRI substudy (optional).

§§Blood pressure, heart rate